PipelineReview.com9h
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint ...
PipelineReview.com10h
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
REDWOOD CITY, CA, USA I3, 2024 I Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging ...
PipelineReview.com10h
Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications
OSLO, Norway I3, 2024 I Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat ...
PipelineReview.com10h
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
Schrödinger will also present preclinical data from its PRMT5-MTA program during a poster session on October 25. Schrödinger scientists have identified a novel series of selective, potent PRMT5-MTA ...
PipelineReview.com10h
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
BASEL, Switzerland I October 23, 2024 I AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal ...